Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.

CONCLUSION: The study provided no rationale for further studying ENMD-2076 as a single agent in FLC.
PMID: 32154962 [PubMed - as supplied by publisher]

Source: The Oncologist - March 9, 2020 Category: Cancer & Oncology Authors: Abou-Alfa GK, Mayer R, Venook AP, O'Neill AF, Beg MS, LaQuaglia M, Kingham PT, Kobos R, Basturk O, Brennan C, Yopp A, Harding JJ, Leong S, Crown J, Hoti E, Leonard G, Ly M, Bradley M, Valentino E, Markowitz D, Zukiwski A, Ren K, Gordan JD Tags: Oncologist Source Type: research